vs

Side-by-side financial comparison of Ginkgo Bioworks Holdings, Inc. (DNA) and i-80 Gold Corp. (IAUX). Click either name above to swap in a different company.

Ginkgo Bioworks Holdings, Inc. is the larger business by last-quarter revenue ($33.4M vs $21.3M, roughly 1.6× i-80 Gold Corp.). i-80 Gold Corp. produced more free cash flow last quarter ($-39.2M vs $-47.7M).

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

i-80 Gold Corp is a mineral exploration and development firm focused on gold and silver asset operations in Nevada, US. It advances high-potential mining projects, using responsible extraction practices to deliver precious metals to global industrial and investment markets.

DNA vs IAUX — Head-to-Head

Bigger by revenue
DNA
DNA
1.6× larger
DNA
$33.4M
$21.3M
IAUX
More free cash flow
IAUX
IAUX
$8.5M more FCF
IAUX
$-39.2M
$-47.7M
DNA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DNA
DNA
IAUX
IAUX
Revenue
$33.4M
$21.3M
Net Profit
$-85.6M
Gross Margin
22.0%
Operating Margin
-211.9%
-291.6%
Net Margin
-401.9%
Revenue YoY
-23.8%
Net Profit YoY
EPS (diluted)
$-1.41
$-0.10

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DNA
DNA
IAUX
IAUX
Q4 25
$33.4M
$21.3M
Q3 25
$38.8M
$32.0M
Q2 25
$49.6M
$27.8M
Q1 25
$48.3M
$14.0M
Q4 24
$43.8M
Q3 24
$89.0M
$11.5M
Q2 24
$56.2M
$7.2M
Q1 24
$37.9M
Net Profit
DNA
DNA
IAUX
IAUX
Q4 25
$-85.6M
Q3 25
$-80.8M
$-41.9M
Q2 25
$-60.3M
$-30.2M
Q1 25
$-91.0M
$-41.2M
Q4 24
Q3 24
$-56.4M
$-43.1M
Q2 24
$-217.2M
$-41.0M
Q1 24
$-165.9M
Gross Margin
DNA
DNA
IAUX
IAUX
Q4 25
22.0%
Q3 25
9.7%
Q2 25
2.9%
Q1 25
20.7%
Q4 24
Q3 24
-42.7%
Q2 24
-171.4%
Q1 24
Operating Margin
DNA
DNA
IAUX
IAUX
Q4 25
-211.9%
-291.6%
Q3 25
-231.8%
-86.7%
Q2 25
-132.1%
-67.4%
Q1 25
-184.1%
-112.3%
Q4 24
-236.3%
Q3 24
-62.0%
-210.0%
Q2 24
-396.7%
-435.2%
Q1 24
-469.1%
Net Margin
DNA
DNA
IAUX
IAUX
Q4 25
-401.9%
Q3 25
-207.9%
-130.8%
Q2 25
-121.6%
-108.5%
Q1 25
-188.2%
-293.3%
Q4 24
Q3 24
-63.3%
-374.5%
Q2 24
-386.4%
-570.8%
Q1 24
-437.3%
EPS (diluted)
DNA
DNA
IAUX
IAUX
Q4 25
$-1.41
$-0.10
Q3 25
$-1.45
$-0.05
Q2 25
$-1.10
$-0.05
Q1 25
$-1.68
$-0.10
Q4 24
$-1.91
Q3 24
$-1.08
$-0.11
Q2 24
$-4.23
$-0.11
Q1 24
$-3.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DNA
DNA
IAUX
IAUX
Cash + ST InvestmentsLiquidity on hand
$422.6M
$63.2M
Total DebtLower is stronger
$174.7M
Stockholders' EquityBook value
$508.6M
$346.8M
Total Assets
$1.1B
$703.4M
Debt / EquityLower = less leverage
0.50×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DNA
DNA
IAUX
IAUX
Q4 25
$422.6M
$63.2M
Q3 25
$495.5M
$102.9M
Q2 25
$559.4M
$133.7M
Q1 25
$325.3M
$13.5M
Q4 24
$561.6M
Q3 24
$616.2M
$21.8M
Q2 24
$730.4M
$47.8M
Q1 24
$840.4M
Total Debt
DNA
DNA
IAUX
IAUX
Q4 25
$174.7M
Q3 25
$175.9M
Q2 25
$175.8M
Q1 25
$197.5M
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
DNA
DNA
IAUX
IAUX
Q4 25
$508.6M
$346.8M
Q3 25
$559.8M
$423.0M
Q2 25
$613.0M
$463.5M
Q1 25
$647.4M
$318.0M
Q4 24
$716.1M
Q3 24
$797.9M
$346.9M
Q2 24
$833.1M
$377.2M
Q1 24
$987.3M
Total Assets
DNA
DNA
IAUX
IAUX
Q4 25
$1.1B
$703.4M
Q3 25
$1.2B
$756.2M
Q2 25
$1.2B
$782.9M
Q1 25
$1.3B
$659.0M
Q4 24
$1.4B
Q3 24
$1.5B
Q2 24
$1.6B
Q1 24
$1.6B
Debt / Equity
DNA
DNA
IAUX
IAUX
Q4 25
0.50×
Q3 25
0.42×
Q2 25
0.38×
Q1 25
0.62×
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DNA
DNA
IAUX
IAUX
Operating Cash FlowLast quarter
$-47.7M
$-34.3M
Free Cash FlowOCF − Capex
$-47.7M
$-39.2M
FCF MarginFCF / Revenue
-142.8%
-184.3%
Capex IntensityCapex / Revenue
0.0%
23.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-93.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DNA
DNA
IAUX
IAUX
Q4 25
$-47.7M
$-34.3M
Q3 25
$-31.6M
$-15.2M
Q2 25
$-40.3M
$-11.3M
Q1 25
$-51.5M
$-22.7M
Q4 24
$-42.4M
Q3 24
$-103.5M
$-23.5M
Q2 24
$-84.4M
$-24.6M
Q1 24
$-89.3M
Free Cash Flow
DNA
DNA
IAUX
IAUX
Q4 25
$-47.7M
$-39.2M
Q3 25
$-18.5M
Q2 25
$-40.3M
$-12.4M
Q1 25
$-59.1M
$-23.1M
Q4 24
$-56.1M
Q3 24
$-118.6M
$-23.8M
Q2 24
$-111.4M
$-25.1M
Q1 24
$-96.0M
FCF Margin
DNA
DNA
IAUX
IAUX
Q4 25
-142.8%
-184.3%
Q3 25
-57.8%
Q2 25
-81.2%
-44.7%
Q1 25
-122.4%
-164.1%
Q4 24
-128.0%
Q3 24
-133.2%
-206.7%
Q2 24
-198.2%
-349.1%
Q1 24
-252.9%
Capex Intensity
DNA
DNA
IAUX
IAUX
Q4 25
0.0%
23.1%
Q3 25
0.0%
10.2%
Q2 25
0.1%
3.9%
Q1 25
15.8%
2.5%
Q4 24
31.3%
Q3 24
16.9%
2.5%
Q2 24
48.1%
7.3%
Q1 24
17.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

IAUX
IAUX

Granite Creek Mining Company$20.3M95%
Ruby Hill Mining Company LLC$991.0K5%
Lone Tree Minning Company$3.0K0%

Related Comparisons